Luspatercept

CHEBI:CHEBI_748956

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2262915
generic_name
LUSPATERCEPT
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
active_ingredient_strength
75 mg/2mL
dosage_form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
route
SUBCUTANEOUS
marketing_start_date
20191108
marketing_category
DRUG FOR FURTHER PROCESSING
pharm_class_pe
Increased Erythroid Cell Production [PE]
pharm_class
Erythroid Maturation Agent [EPC]
package_marketing_start_date
08-NOV-19
labeler_name
Celgene Corporation
nui
N0000194025
manufacturer_name
Celgene Corporation
brand_name
Reblozyl
brand_name_base
Reblozyl
product_ndc
59572-775
application_number
BLA761136
spl_id
2617bdb2-26cd-f674-e063-6394a90a4583
active_ingredient_name
LUSPATERCEPT
package_ndc
59572-775-01
package_description
1 VIAL, GLASS in 1 CARTON (59572-775-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS
unii
AQK7UBA1LS
spl_set_id
82f4d266-3f52-41eb-86ba-0abf3cf468e8
pharm_class_epc
Erythroid Maturation Agent [EPC]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class